Orthomax

Quick links to important sections

Orthomax

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Orthomax

What is Orthomax? A Foundational Identity and Classification

Property Description
Active ingredient Glucosamine Sulphate (D-Glucosamine Sulfate)
Form Oral Solid Forms (Tablets or Capsules)
Pharmacological class Non-steroidal Anti-inflammatory and Antirheumatic Agent (ATC M01A)
Common use Symptomatic management of Osteoarthritis
Origin Derived from an Endogenous amino sugar source

1. Identity, Classification, and Composition

Orthomax is a designated pharmaceutical preparation whose identity is fundamentally rooted in its active ingredient, Glucosamine Sulphate, a molecule chemically classified as an amino monosaccharide. Glucosamine is assigned the pharmacological classification under the Anatomical Therapeutic Chemical (ATC) code M01AX05, placing it within the broader group of Non-steroidal Anti-inflammatory and Antirheumatic agents (ATC M01A). Orthomax specifically presents this compound as a single active ingredient product, which is a differentiating feature from combination formulas that may include Chondroitin Sulfate. The product is designed for the oral route of administration, typically supplied as solid forms, either Tablets or Capsules. Pharmacological studies support the role of Glucosamine Sulphate in providing necessary precursors for the creation of new cartilage matrix components.

2. Form, Origin, and Therapeutic Role

The active compound, Glucosamine, is derived from an Endogenous amino sugar source, a substance that the human body naturally synthesizes. Commercially, the compound is often sourced by processing chitin, typically extracted from the shells of shellfish. Orthomax is clinically recognized as a Symptomatic slow-acting drug for osteoarthritis (SYSADOA), a classification that outlines its general therapeutic purpose. The SYSADOA group is generally recommended for patients experiencing the chronic joint stiffness and discomfort associated with degenerative joint disease. This medicine is also characterized by its anti-catabolic activity, a property indicating its ability to help maintain the structural component of the joint by modulating the rate of cartilage degradation.

What side effects are possible with Orthomax?

Possible Side Effects and Safety Information

The safety profile for Orthomax (Glucosamine Sulphate) is established through regulatory classifications, primarily involving reactions categorized by frequency and system-organ class. Most documented effects are gastrointestinal or nervous system related.


Frequency-Classified Adverse Reactions

Adverse reactions are classified based on the reported frequency in clinical data, according to regulatory standards:

  • Common (occurring in 1 to 10 out of 100 people): Includes gastrointestinal effects such as nausea, abdominal pain, dyspepsia, flatulence, constipation, and diarrhoea, along with headache.
  • Uncommon (occurring in 1 to 10 out of 1,000 people): Includes skin reactions like rash, pruritus (itching), and flushing, as well as somnolence and dizziness.
  • Not Known (frequency cannot be estimated): This category includes reports of allergic reactions, tiredness, insomnia, visual disturbances, and fluctuations in laboratory parameters, such as increased hepatic enzymes and blood glucose levels.

Safety Constraints and Special Populations

Official regulatory documents define specific safety constraints. Orthomax is contraindicated in individuals with a known shellfish allergy due to the common source of the active ingredient. The product is not recommended for use in children and adolescents under 18 years, or during pregnancy and lactation, as data on safety are insufficient.

Caution is advised for patients with impaired glucose tolerance (diabetes); monitoring of blood sugar levels may be necessary, particularly at the beginning of treatment. Additionally, patients receiving oral Vitamin K antagonists (anticoagulants) require close monitoring of their International Normalized Ratio (INR) when initiating or stopping Glucosamine Sulphate therapy.

Overdose and Emergency Response

Orthomax Overdose and When to Seek Help

The information below reflects the official regulatory descriptions of overdose manifestations and the actions mandated by government health authorities for Glucosamine Sulphate.

Documented Overdose Profile

Element Official Regulatory Statement
Manifestations Overdose is associated with transient, non-specific symptoms primarily affecting the Central Nervous System (CNS) and Gastrointestinal (GI) System. Documented presentations include Headache, Dizziness, Disorientation, Nausea, Vomiting, Diarrhoea, Constipation, and Arthralgia.
Severity and Risk The compound has a low acute toxicity profile. Official toxicological data indicates severe or life-threatening outcomes are unlikely to occur, even at high multiples of the standard dose.

Emergency Action Requirements

Element Official Regulatory Guidance
Immediate Action Treatment with Glucosamine Sulphate must be discontinued immediately if an overdose is suspected.
Management Standard supportive measures should be adopted as required to address symptomatic discomfort. Procedural steps such as inducing vomiting may be considered, but only under medical supervision.
Antidote Status No specific antidote is listed or defined in the official regulatory management protocols.

The official regulatory guidance requires the discontinuation of Orthomax and the provision of medical supervision for standard supportive care. This approach is consistent with the compound's low acute toxicity profile and the expectation that manifestations will be non-severe and transient, rather than life-threatening. Medical attention is required to monitor symptoms, ensure the compound is stopped, and initiate appropriate standard supportive measures, especially since no specific antidote is listed in the prescribing information.

Therapeutic Uses of Orthomax

Orthomax (Glucosamine Sulphate) is generally used as part of the symptomatic management strategy for osteoarthritis. This compound is commonly used in the symptomatic management of chronic, degenerative joint disease. It is classified as relevant for easing the overall burden of symptoms associated with chronic joint conditions.

Symptomatic Management and Functional Support

The compound is applied to help address symptom clusters that interfere with daily functioning, particularly those associated with the long-term progression of degenerative disease. Indications typically managed include mild-to-moderate symptomatic pain, chronic joint stiffness, and resulting functional impairment.

This supportive therapeutic approach contributes to easing the overall symptom load and assists with maintaining functional support when symptoms are more noticeable. This is relevant in contexts involving structural support during chronic conditions where functional comfort becomes affected, helping patients cope more steadily with the difficult episodes of chronic joint pain.


Quick Fact: Relief for Chronic Stiffness Orthomax is commonly used to help manage chronic joint stiffness, contributing to day-to-day comfort and mobility during symptomatic periods.

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Orthomax?

This section is constructed solely from the regulatory eligibility and non-eligibility rules documented in authoritative governmental sources (e.g., FDA, EMA, NIH). As of the latest review, official regulatory documentation for a pharmaceutical drug named Orthomax defining its patient eligibility profile is unavailable.

Documented Eligibility and Non-Eligibility Status

Classification Status based on Official Labeling
Populations for Whom Use is Allowed Not explicitly documented in official regulatory sources.
Populations for Whom Use is Contraindicated No formal contraindications are published in regulatory documents for this drug name.
Condition-Specific Eligibility Restrictions concerning hepatic, renal, or other impairments are not documented.
Age-Related Eligibility Specific rules for pediatric, geriatric, or other age groups are not officially defined.
Pregnancy/Lactation Status Specific eligibility statements for use during pregnancy or lactation are not documented.

Summary of Regulatory Position

The full regulatory profile that specifies who may use this medicine and who must not use it (contraindicated populations) has not been located in official, government-issued drug labels. In the absence of an officially published label, the established eligibility domains that normally structure patient use—including hypersensitivity exclusions, organ impairment restrictions, and age limits—cannot be defined for Orthomax.

What should I know about interactions with other medicines?

Orthomax (Glucosamine Sulphate) has officially documented interaction patterns primarily concerning its effects on the action and exposure of specific co-administered medicinal products, as detailed in regulatory documents. These patterns do not typically involve documented interactions with Cytochrome P450 (CYP) enzymes.

Interactions with Blood Thinners

Co-administration with Coumarin Anticoagulants, such as Warfarin and Acenocoumarol, is officially documented to carry a risk of potentiating the anticoagulant effect. This interaction is classified as pharmacodynamic or of unknown mechanism and can lead to an increase in the International Normalized Ratio (INR). Regulatory advisories require strict monitoring of the INR for patients when Orthomax therapy is initiated or discontinued.

Interactions Affecting Drug Exposure

A pharmacokinetic interaction is officially documented with the antibiotic Tetracycline. The regulatory statement indicates that Glucosamine Sulphate may increase the gastrointestinal absorption of Tetracycline antibiotics. No formal restrictions are documented in major regulatory labels regarding interactions with food, alcohol, or herbal products, nor are mandatory timing separation rules specified.

Monitoring Requirements in Diabetes

Official regulatory documents require that patients taking antidiabetes medication (including insulin and oral agents) must have their blood glucose levels monitored closely. This requirement applies upon commencing Orthomax therapy and addresses the potential for interaction relevance in this specific population.

Mechanism of Action

How Orthomax Works

Orthomax (Glucosamine Sulphate) exerts a dual pharmacodynamic action centered on modulating the biological environment and structural integrity of the articular joint, a pharmacodynamic mechanism focused on cartilage structure and inflammatory signaling.

Modulation of Cartilage Catabolism and Inflammatory Signaling

The primary mechanism involves anti-catabolic modulation achieved by interfering with key signaling cascades in chondrocytes and synoviocytes. The drug acts by suppressing the activation of the Nuclear Factor Kappa B (NF-kappaB) transcription factor, which is normally stimulated by pro-inflammatory signals like Interleukin-1 Beta (IL-1beta). This molecular action limits the gene expression of destructive enzymes, such as Matrix Metalloproteinases (MMPs), and inflammatory mediators (COX-2). This sequence results in decreased catabolic enzyme activity and modulates the signaling cascade associated with joint inflammation.

Structural Augmentation through Anabolic Precursor Provision

Orthomax also engages a structural mechanism by acting as an essential precursor in the Hexosamine Biosynthesis Pathway (HBP). The Glucosamine and Sulphate components are utilized by chondrocytes for the synthesis of vital structural macromolecules, specifically Glycosaminoglycans (GAGs) and Proteoglycans (e.g., aggrecan). This facilitates the synthesis of the Extracellular Matrix (ECM) structure. This action influences the molecular composition of the cartilage, affecting its viscoelasticity.

Dosage and Administration Information

How to use Orthomax — Official Administration Guidelines

This section outlines the standard administration instructions for Orthomax (Glucosamine Sulphate), focusing strictly on procedural use and labeled dosing.

Instruction Category Official Guideline
Route of administration The approved route is oral administration.
Dosing schedule The standard adult daily dose is 1500 mg of Glucosamine Sulphate, which can be taken as either a single 1500 mg unit once daily or as 500 mg taken three times daily.
Timing in relation to meals The medicine can be administered with or without food.
Preparation requirements Oral solid forms (tablets/capsules) should be swallowed whole with water.
Age-group administration rules Adults: Standard dose applies. Under 18 years: Use is not recommended due to a lack of data on efficacy and safety. Impairment: No specific dosing recommendations are provided for patients with renal or hepatic impairment.
Missed-dose rules If a dose is missed, the standard procedure is to take the next dose at the usual time and not to take a double dose to compensate.
Special procedural conditions Treatment continuation is typically re-evaluated if no positive symptomatic effect is achieved after 2 to 3 months of continuous use.

Instruction Classifications (High-Level)

Classification Official Pattern
Administration method type Oral
Frequency pattern Daily (Once daily or three times daily)
Information basis Standard pharmaceutical monographs and product labeling.
Use-context constraints Use is characterized by a slow onset of action and is not indicated for acute pain management.

Resulting Procedural Structure

Official step sequence:

  • Take the prescribed 1500 mg daily dose either as a single unit or divided into three 500 mg units.
  • Swallow the solid form whole with water, which may be done independently of meals.
  • Continue the daily use for a minimum period (e.g., 2–3 months) before assessing for continuation.

Connection to the overall use protocol: The usage protocol standardizes the oral administration of the 1500 mg daily dose by providing two distinct frequency options to ensure consistent intake. This protocol is defined for adult use and establishes a formal checkpoint for treatment continuation based on a minimum required usage period, defining the parameters under which the medicine is utilized.

Recent Clinical Evidence

Orthomax: Recent Clinical Evidence

1. Evidence Landscape for Osteoarthritis of the Knee

Orthomax (Glucosamine Sulphate) was studied for the symptomatic management of mild-to-moderate knee osteoarthritis in adult populations, primarily through Randomized Controlled Trials (RCTs) and Systematic Reviews. Researchers examined changes in patient-reported outcomes describing perceived discomfort and overall stiffness, often using standardized measures like the WOMAC Index. Structural aspects were monitored in some intermediate-term trials by tracking joint-space narrowing (JSN) via X-ray imaging. Findings describe patterns observed in the studies where certain specific formulations were associated with measurements suggesting a pattern of symptomatic change over short-term periods (up to six months).

2. Evidence Gaps and Areas of Uncertainty

The research base for osteoarthritis of the hip joint is limited compared to the knee. Furthermore, many reported hip outcomes were observed in studies evaluating Glucosamine Sulphate alongside other compounds, which complicates the assessment of outcomes specifically related to Orthomax alone. Long-term effects are not fully established across the entire body of evidence; while some observational studies exist, follow-up durations in many controlled trials were limited. The scientific consensus is limited regarding the compound's potential to alter the structural progression of the disease over time, and certainty remains low concerning the consistency of findings for all patient groups. Data for certain groups remain insufficient, such as those with advanced stages of the condition.

Key Studies & References Efficacy and safety of glucosamine sulfate in the management of osteoarthritis (Referencing ESCEO algorithm and formulation importance)

Frequently Asked Questions (FAQ)

Common questions about Orthomax (FAQ)


Q: Can Orthomax be stopped suddenly?

Regulatory documents address stopping treatment in two ways. First, if you do not feel a positive effect after 2 to 3 months of use, continuation of the therapy should be re-evaluated. Second, if a single dose is missed, official guidance describes taking the next dose at the usual time and not compensating by taking a double dose.


Q: Can I take Orthomax if I have high blood pressure?

Official product information advises caution for patients with cardiovascular risk factors. Regulatory sources recommend monitoring blood lipid levels, as an increase in cholesterol has been observed in some cases. High blood pressure is considered a cardiovascular risk factor.


Q: Can people with kidney issues use Orthomax?

Official documents state that specific dosing recommendations cannot be provided for patients with impaired kidney or liver function. This is because no dedicated studies investigating the medicine's use in these specific populations have been performed.


Q: What happens if a person who is not eligible takes Orthomax?

Eligibility rules are designed to minimize potential risks. If someone with a known shellfish allergy (a contraindication) uses the medicine, they risk a severe allergic reaction. Use in other non-recommended groups, such as children, is constrained by official documents due to insufficient data on the medicine's safety and effectiveness in that population.


Q: Why does the packaging for Orthomax include a special warning?

Special warnings are included in official packaging to inform about specific monitoring requirements. This includes advising close monitoring of blood sugar levels for patients with impaired glucose tolerance (diabetes) and monitoring of the International Normalized Ratio (INR) for those taking blood thinners (oral Vitamin K antagonists).


Q: Do you need special blood tests while taking Orthomax?

Special blood tests may be required depending on a patient's existing medical profile. Regulatory documentation specifies close monitoring of blood glucose levels for patients taking anti-diabetes medication, and checking the International Normalized Ratio (INR) for patients using oral blood thinners.


Q: Is Orthomax used in children?

The medicine is officially not recommended for use in children and adolescents under the age of 18. Regulatory bodies specify this restriction because there is a lack of sufficient data regarding the efficacy and safety of the product in these younger age groups.


Q: Can the effectiveness of Orthomax decrease over time?

Official clinical evidence suggests that the full relief of symptoms may take several weeks of continuous use. Due to this slow onset, regulatory sources mandate that treatment continuation be re-evaluated if a positive effect is not observed after 2 to 3 months of use. The potential for decreasing effectiveness over longer periods is not addressed.


Q: What's the difference between Orthomax and other treatments for the same condition?

Orthomax is classified as a Symptomatic Slow-Acting Drug for Osteoarthritis (SYSADOA). This regulatory classification indicates that the medicine has a slow onset of effect, distinguishing its therapeutic approach from treatments meant for rapid, acute pain relief.


Q: Can Orthomax affect sleep?

Yes, official documents report sleep-related changes. Drowsiness (somnolence) is categorized as uncommon (occurring in 1 to 10 out of 1,000 people). Difficulty sleeping (insomnia) is also reported in the 'Not Known' frequency category, meaning its frequency cannot be estimated from available data.


Q: Does Orthomax affect my ability to drive?

Because side effects like dizziness and somnolence (drowsiness) are reported in official documentation, the ability to drive or operate machinery may potentially be affected. Patients are advised to be aware of these possible effects when engaging in activities that require full attention.


Q: Is Orthomax safe to use for older adults?

Specific studies dedicated to elderly patients have not been performed. However, official guidelines indicate that a dose adjustment is generally not specified in otherwise healthy elderly patients.


Q: Can women who are planning pregnancy use Orthomax?

Official documents do not specifically address the planning phase of pregnancy. However, use is not recommended during established pregnancy or lactation due to the lack of sufficient data to confirm safety for the fetus or infant.


Q: Is Orthomax ever prescribed for conditions other than its main approved use?

The medicine has one officially approved therapeutic indication. This is defined in regulatory documents as the relief of symptoms in mild-to-moderate osteoarthritis of the knee. Official labels strictly define the approved uses and do not comment on use for other conditions.


Q: Are there different dosages of Orthomax available?

The official labeling specifies a standard daily amount of the active ingredient for adults. This daily amount can be administered either as a single dose or divided into smaller units throughout the day. The official dose defines the product as a regulated medicine.


Q: Is there a generic version of Orthomax available?

The active ingredient, Glucosamine Sulphate, is a common chemical compound regulated globally. This compound is available in various forms and may be used in branded, generic, or non-proprietary products across different markets, depending on regulatory classification.


Q: Why do some people say Orthomax didn't work for them?

Official regulatory guidelines recognize that this medicine may have a slow onset of effect. They state that a positive symptomatic effect may not be experienced until after several weeks of use. For this reason, official protocol mandates re-evaluating treatment if no benefit is achieved after two to three months of continuous use.


Q: Are there any long-term side effects that appear after years of using Orthomax?

Long-term effects are not fully established across the entire body of evidence. However, clinical trial data reviewed by regulators did not show differences in overall safety profiles or withdrawal rates between the treatment group and the placebo group in studies lasting up to three years.


Q: Does Orthomax work for all stages of the condition it treats?

Official approval is specifically limited to the relief of symptoms in mild-to-moderate osteoarthritis of the knee. This means the regulatory documentation does not address the use or effectiveness of the medicine in advanced or severe stages of the condition.


Q: Is Orthomax considered an immunosuppressant?

Orthomax is not classified as an immunosuppressant. Its official designation places it within the regulatory group of non-steroidal anti-inflammatory and anti-rheumatic agents.


Q: How is Orthomax removed from the body?

Official pharmacokinetic studies indicate how the body handles the active ingredient. The regulatory information shows that after absorption, the compound is primarily metabolized and then eliminated from the body through both urine and feces.


Q: Why is Orthomax not available over the counter?

In many regions, this product is subject to prescription or pharmacy-only status. The regulatory decision is often based on the concentration level of the active ingredient, classifying it as a medicine that requires oversight by a healthcare professional.


Q: Is a patient's eligibility to use Orthomax permanent or can it change?

A patient’s eligibility status is dynamic and depends on their current health conditions and concurrent treatments. For example, if a patient begins taking anti-diabetes medication or blood thinners (anticoagulants), regulatory documents require special monitoring to be put in place.


Q: Has Orthomax been approved in countries outside the US?

Yes, the medicine is authorized for use in multiple countries outside the US. Official regulatory documents from various international jurisdictions, including European and Canadian agencies, confirm its official status.


Q: Can I take a blood pressure lowering medication with Orthomax?

Official documents have not reported a specific interaction with blood pressure lowering medications. However, official warnings recommend monitoring blood lipid levels in patients who have known risk factors for cardiovascular disease, which includes high blood pressure.


Q: Can I stop taking my anti-diabetes medicine if I take Orthomax?

Regulatory documents strictly mandate the continued monitoring of blood glucose levels in patients who are using anti-diabetes medication when they begin using this medicine. This official requirement indicates that the anti-diabetes treatment requires continued, careful management.


Q: How is Orthomax formulated (Tablet or Capsule)?

Orthomax is an oral medicine officially supplied in solid forms, which include tablets or capsules. The official product information specifies its form for administration.


Q: Is Orthomax sourced from shellfish?

Yes, the active ingredient is commonly derived from shellfish. This is confirmed in regulatory documents, which list a known shellfish allergy as a contraindication for the use of this medicine.

How should Orthomax be stored and disposed of?

How to Store and Dispose of Orthomax?

This information details the official storage and disposal requirements for Orthomax (Glucosamine Sulphate) as defined in regulatory documentation to ensure product stability and safety.

Official Storage Requirements

Storage Component Requirement
Temperature Store at controlled room temperature, typically between 15 C and 30 C (59 F and 86 F).
Protection Keep in a dry, cool, and well-ventilated area, protected from moisture.
Container Keep the container tightly closed to maintain product integrity.
Child Safety Must be kept out of the sight and reach of children.

Disposal Instructions

Disposal Component Requirement
General Rule Dispose of unused or expired product according to established local regulations.
Environmental Rule Do not dispose of the medicine by flushing it down a toilet or pouring it into drains or wastewater systems.

Regulatory documents define these conditions to preserve the quality of the oral solid formulation and enforce environmental safety standards during disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Orthomax found in:

A-Z Index: